In bladder cancer cells, miR-106a inhibits the expression of cyclin D1 and CDK6 and enhances the p21CIP1/WAF1 pathway, which arrests the cell cycle at the G1 phase [127]. Here, CDKN1A is linked to urinary bladder cancer.